Literature DB >> 17544971

Role of radiologic modalities in the management of non-alcoholic steatohepatitis.

Phunchai Charatcharoenwitthaya1, Keith D Lindor.   

Abstract

During the last decade, the role of radiologic modalities in management of patients who have fatty liver disease has expanded. Ultrasonography has been used as a noninvasive alternative to biopsy for monitoring patients who have hepatic steatosis, but MRI is more appealing than ultrasonography to denote minor changes in hepatic fat content. Distinguishing patients who have non-alcoholic steatohepatitis from steatosis alone has become of clinical importance; however, the differences are not apparent with any radiologic modalities. Several modalities have been developed to noninvasively and accurately quantify hepatic fat content and diagnose steatohepatitis. In the future, radiologic modalities might be used to monitor the natural history of the disease or evaluate therapeutic interventions in patients who have non-alcoholic fatty liver disease.

Entities:  

Mesh:

Year:  2007        PMID: 17544971     DOI: 10.1016/j.cld.2007.02.014

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  49 in total

1.  A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

Authors:  Zobair M Younossi; Sandra Page; Nila Rafiq; Aybike Birerdinc; Maria Stepanova; Noreen Hossain; Arian Afendy; Zahra Younoszai; Zachary Goodman; Ancha Baranova
Journal:  Obes Surg       Date:  2011-04       Impact factor: 4.129

Review 2.  Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.

Authors:  Scott B Reeder; Irene Cruite; Gavin Hamilton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2011-09-16       Impact factor: 4.813

Review 3.  Quantification of liver fat with magnetic resonance imaging.

Authors:  Scott B Reeder; Claude B Sirlin
Journal:  Magn Reson Imaging Clin N Am       Date:  2010-08       Impact factor: 2.266

4.  In vivo characterization of the liver fat ¹H MR spectrum.

Authors:  Gavin Hamilton; Takeshi Yokoo; Mark Bydder; Irene Cruite; Michael E Schroeder; Claude B Sirlin; Michael S Middleton
Journal:  NMR Biomed       Date:  2010-12-12       Impact factor: 4.044

5.  Detection of non-alcoholic steatohepatitis in patients with morbid obesity before bariatric surgery: preliminary evaluation with acoustic radiation force impulse imaging.

Authors:  F Guzmán-Aroca; M D Frutos-Bernal; A Bas; J A Luján-Mompeán; M Reus; Juan de Dios Berná-Serna; P Parrilla
Journal:  Eur Radiol       Date:  2012-06-01       Impact factor: 5.315

6.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

7.  Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study.

Authors:  Lauren J Kim; Michael A Nalls; Gudny Eiriksdottir; Sigurdur Sigurdsson; Lenore J Launer; Annemarie Koster; Paulo H M Chaves; Birna Jonsdottir; Melissa Garcia; Vilmundur Gudnason; Tamara B Harris
Journal:  Obesity (Silver Spring)       Date:  2010-12-23       Impact factor: 5.002

Review 8.  Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging.

Authors:  Yingzhen N Zhang; Kathryn J Fowler; Gavin Hamilton; Jennifer Y Cui; Ethan Z Sy; Michelle Balanay; Jonathan C Hooker; Nikolaus Szeverenyi; Claude B Sirlin
Journal:  Br J Radiol       Date:  2018-06-06       Impact factor: 3.039

9.  Synergistic effect of fatty liver and smoking on metabolic syndrome.

Authors:  Po-Hsin Chiang; Tsui-Yen Chang; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

10.  Echocardiography and dual-energy x-ray absorptiometry in the elderly patients with metabolic syndrome: a comparison of two different tecniques to evaluate visceral fat distribution.

Authors:  G Stramaglia; A Greco; G Guglielmi; A De Matthaeis; G L Vendemiale
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.